Douglas Love Sells 5,021 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 5,021 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $2.95, for a total value of $14,811.95. Following the transaction, the chief executive officer now directly owns 351,554 shares in the company, valued at approximately $1,037,084.30. The trade was a 1.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Annexon Stock Up 5.6 %

ANNX opened at $2.85 on Thursday. Annexon, Inc. has a 52 week low of $2.63 and a 52 week high of $8.40. The business has a 50 day moving average price of $4.33 and a two-hundred day moving average price of $5.59. The company has a market cap of $303.78 million, a PE ratio of -2.71 and a beta of 1.07.

Institutional Investors Weigh In On Annexon

Several large investors have recently modified their holdings of ANNX. BNP Paribas Financial Markets acquired a new position in Annexon in the 4th quarter valued at $59,000. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Annexon in the fourth quarter valued at about $77,000. E Fund Management Co. Ltd. increased its stake in shares of Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC raised its holdings in Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after purchasing an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Annexon in the fourth quarter valued at about $98,000.

Analyst Ratings Changes

ANNX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon currently has an average rating of “Buy” and a consensus target price of $15.80.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.